Hutch News

Hutch News

Stories tagged 'immunotherapy'

New guide helps clinicians navigate immunotherapy revolution in Merkel cell carcinoma

‘Real-world’ review accompanies new clinical care guidelines in rare skin cancer

June 28, 2018 | By Susan Keown / Fred Hutch News Service

Fred Hutchinson Cancer Research Center researchers have published a new guide to help clinicians navigate a recent revolution in care for advanced Merkel cell carcinoma, a rare and deadly skin cancer.

View story >


His immune system eradicated his melanoma. Could other patients’ bodies be taught to do the same thing?

How one man’s T cells are guiding the development of next-gen immunotherapies

June 19, 2018 | by Susan Keown / Fred Hutch News Service

Chris Pope's immune system eradicated his stage 4 melanoma on an immunotherapy clinical trial. Is it possible to genetically reprogram other patients' to do the same thing?

View story >


Fred Hutch at ASCO

Immunotherapy advances, insights into health economics and leadership awards dominate oncology gathering

June 5, 2018 | By Fred Hutch staff

Immunotherapy advances, insights into health economics and leadership awards dominate oncology gathering

View story >


Immunotherapy has long-term benefit for patients with advanced Merkel cell carcinoma

‘Incredibly big change’ in treatment of deadly skin cancer, new data show

June 4, 2018 | by Susan Keown / Fred Hutch News Service

Immunotherapy drugs have transformed the treatment of a deadly skin cancer, Merkel cell carcinoma. New trial results show these drugs help many patients survive much longer than would otherwise be possible.

View story >


Pacific NW Magazine profiles Fred Hutch’s pursuit of cancer cures

Seattle Times’ Sunday feature looks at the melding of expertise, drive and technology making new cures possible

May 17, 2018 | By Fred Hutch staff

Cover story of Seattle Times’ Pacific NW Magazine explores why Fred Hutchinson Cancer Research Center is closing in on cancer cures.

View story >


Tinkering with T cells

How researchers are tweaking engineered immune cells’ cancer-targeting receptors — and why it matters

May 15, 2018 | By Susan Keown / Fred Hutch News Service

These immune cells are the cornerstone of emerging cancer therapies. And their unimaginably tiny, cancer-targeting molecular weapons — their receptors — are the focus of intense scientific tinkering.

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.